The week in health tech, explained in plain English.Get the free newsletter →
November 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

Indiana Hospital Ties Service Expansion to Employee Plan Switch

An Indiana hospital says changing its own employee health insurance freed up money to expand patient services, according to Becker's Hospital Review. The move puts a health system in the same seat as any large employer wrestling with the cost of covering its workforce.

The backdrop is a traditional group health plan under strain. Commercial insurance costs have reached record highs, driven by compounding pressures: specialty medication spend, rising stop-loss insurance premiums, and growing behavioral health utilization. Those forces are pushing employers of all kinds to look past the standard fully insured model.

Alternatives are proliferating. Employers are turning to direct contracting with providers, narrow networks that steer patients to lower-cost care, and level funding that blends self-insurance with predictable monthly payments. For a hospital, the calculus is unusual, because it is both a large employer and a provider of the care it pays for. The reported result was enough savings to reinvest in services, a signal other systems are watching.

More in Finance

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.